NBY vs OGEN vs SIGA vs PRPH

For growth investors, NovaBay Pharmaceuticals, Inc.

(NBY) is the stronger pick with -6. 4% revenue growth year-over-year, versus -84. 7% for ProPhase Labs, Inc. (PRPH). SIGA Technologies, Inc. (SIGA) offers the better valuation at 14. 5x trailing P/E (2. 8x forward), making it the more compelling value choice. Analysts rate SIGA Technologies, Inc. (SIGA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, SIGA Technologies, Inc.

(SIGA) delivered a total return of +7. 9%, compared to -99. 9% for Oragenics, Inc. (OGEN). Over 10 years, the gap is even starker: SIGA returned +772. 1% versus OGEN's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), SIGA Technologies, Inc.

(SIGA) is the lower-risk stock at 1. 09β versus NovaBay Pharmaceuticals, Inc. 's 2. 51β — meaning NBY is approximately 130% more volatile than SIGA relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 27% for Oragenics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovaBay Pharmaceuticals, Inc.

(NBY) is pulling ahead at -6. 4% versus -84. 7% for ProPhase Labs, Inc. (PRPH). On earnings-per-share growth, the picture is similar: NovaBay Pharmaceuticals, Inc. grew EPS 98. 2% year-over-year, compared to -185. 0% for Oragenics, Inc.. Over a 3-year CAGR, NBY leads at -1. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

SIGA Technologies, Inc.

(SIGA) is the more profitable company, earning 24. 6% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SIGA leads at 25. 1% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — SIGA leads at 68. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, SIGA (12.

5% yield) pays a dividend. NBY, OGEN, PRPH do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09), 12. 5% yield, +772. 1% 10Y return). Oragenics, Inc. (OGEN) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +772. 1%, OGEN: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NBY is a small-cap quality compounder stock; OGEN is a small-cap quality compounder stock; SIGA is a small-cap deep-value stock; PRPH is a small-cap quality compounder stock. SIGA pays a dividend while NBY, OGEN, PRPH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.